Houman is a Managing Partner at SV Health Investors and co-founded Alchemab in 2019.
Alongside Alchemab, Houman has founded eight other SV portfolio companies – Sitryx, Enara Bio, Zarodex, TRex Bio, Catamaran Bio, Cellinta, Mestag and Imbria. Houman also serves on the Dementia Discovery Fund (DDF) Investment Committee. Prior to joining SV, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. He went on to become Vice President and Head of the Clinical Science Group at UCB.
Houman is a cardiologist by training, gaining his BM BCh and a DPhil, from the University of Oxford. He was appointed as an Honorary Consultant Cardiologist at the John Radcliffe Hospital in Oxford in 2011. He is also Visiting Professor and head of Experimental Therapeutics at the University of Oxford.